论文部分内容阅读
目的 探讨小细胞肺癌脑转移综合治疗的疗效，方法 自１９８５．１～１９９３．１，共９８例小细胞肺癌颅内转移患者，按治疗方法不同，分为单纯化疗组（Ａ组），单纯放疗组（Ｂ组），综合治疗组（Ｃ组），Ａ组３０例，Ｂ组３２例，Ｃ组３６ 例，结果Ａ、Ｂ、Ｃ三组的１、２年生存率及中位生存期分别为：Ａ组０，０，３．２个月；Ｂ组２５％ 、９．４％ 、６．５个月；Ｃ组３０．５％ 、１９．４％ 、９．６个月Ｂ、Ｃ两组１、２年生存率及中位生存期明显高于Ａ组，Ａ、Ｂ、Ｃ三组单发转移灶中位生存期分别为为３．４，７．２，１０．８个月。多发转移灶中位生存期分别为２．６、５．８、８．４个月。肺内原发灶控制患者中位生存期分别为４．４，７，１２个月，肺内原发灶未控制患者，中位生存期分别为２．６，５．８，９．２个月。如何提高肺部原发灶控制率，提高小细胞肺癌颅内转移疗效，仍需进一步探讨，结论 在小细胞肺癌的综合治疗中，放疗＋ 化疗可提高患者生存率，只要病人条件允许，全脑预防照射是有积极意义的，可否提高生存率，应作随机分组临床研究。
Objective To explore the curative effect of comprehensive treatment of brain cell metastasis of small cell lung cancer from 1985.1 to 1993.1. A total of 98 patients with intracranial metastases of small cell lung cancer were divided into chemotherapy group (group A) and radiotherapy alone according to different treatment methods. Group (Group B), Comprehensive Treatment Group (Group C), Group A 30 patients, Group B 32 patients, Group C 36 patients, results A, B, C three-year survival rate and median survival period were For: A group 0,0,3.2 months; B group 25%, 9.4%, 6.5 months; C group 30.5%, 19.4%, 9.6 months B, C The 1-year and 2-year survival rates and median survival time were significantly higher in the two groups than in the A group. The median survival time of the single metastases in the three groups was 3.4, 7.2 and 10.8 months, respectively. . The median survival of multiple metastases was 2.6, 5.8, and 8.4 months, respectively. The median survival time of primary lung control patients was 4.4, 7, and 12 months, and the primary lung tumors were not controlled. The median survival time was 2.6, 5.8, and 9.2, respectively. month. How to improve the control rate of primary tumors in the lung and improve the efficacy of intracranial metastasis in small cell lung cancer still needs further investigation. Conclusion In the comprehensive treatment of small cell lung cancer, radiotherapy + chemotherapy can improve the survival rate of patients, as long as the patient conditions allow, the whole brain Preventive irradiation is of positive significance. Whether it can improve survival rate should be randomized into clinical studies.